Abstract: The invention provides a compound of formula (I) wherein: A, B, C, D, W, X, Y and Z are each independently selected from H and OH; or a salt thereof; for use in the treatment and/or prophylaxis of a condition, disease or disorder in a subject, wherein the compound or salt is orally administered to a subject in a daily amount of from 2.8 to 6.6 mmol per day, over a period of at least 21 days. Also are provided are the compound of formula (I) for use in increasing mitophagy and/or autophagy, maintaining and/or improving muscle function and administration as a dietary, nutritional and/or health supplement.
Type:
Grant
Filed:
March 8, 2018
Date of Patent:
April 30, 2024
Assignee:
Amazentis SA
Inventors:
Christopher Rinsch, Penelope Andreux, Anurag Singh
Abstract: A use of a compound or a medicinal derivative thereof in inhibiting absent in melanoma 2 (AIM2) protein activity is provided, and belongs to the field of protein inhibitory medicine technology. Compared with traditional broad-spectrum immunomodulators, the compound has a strong targeting effect, and is more accurate, rapid, effective, safe and stable. Moreover, the compound has a strong binding force with human AIM2 protein and mouse AIM2 protein, and binding constants are as high as 1.029E-5M and 1.033E-5M respectively. Compared with traditional biological inhibitors, the compound has advantages of easy storage, stable activity, small molecular weight, lower production cost and easy absorption.
Abstract: The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
April 15, 2021
Date of Patent:
March 26, 2024
Assignee:
ACTIMED THERAPEUTICS LIMITED
Inventors:
Andrew J. S. Coats, Stefan Anker, Jochen Springer
Abstract: Novel pyrido[4?,3?:4,5]pyrrolo[3,2-b][1,7]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrido[4?,3?:4,5]pyrrolo[3,2-b][1,7]naphthyridine compounds are useful as anticancer and/or antitumor agents.
Abstract: A temozolomide compound according to formula (I) is described, wherein R1, L1, and X are defined herein. The temozolomide compound can be used to prepare polymers comprising temozolomide. Additionally, the polymers comprising temozolomide can be particularly useful in the treatment of certain diseases.
Type:
Grant
Filed:
March 1, 2021
Date of Patent:
February 27, 2024
Assignee:
UNIVERSITY OF MASSACHUSETTS
Inventors:
Todd Emrick, Matthew Skinner, Sarah M. Ward, Banishree Saha
Abstract: A method for rapidly improving cardiovascular function, reducing arterial stiffness and reversing calcification of a blood vessel in a mammal comprising administering to the mammal an effective amount of vitamin K for a period of less than 6 months. Also a method for increasing endothelial nitric oxide production in mammals comprising administering to the mammal an effective amount of vitamin K for a period of less than 6 months. The vitamin K can be administered together with additional substances such as vitamin D.
Type:
Grant
Filed:
April 1, 2019
Date of Patent:
February 27, 2024
Assignee:
NATTOPHARMA AS
Inventors:
Stefan Chlopicki, Katarzyna Maresz, Anna Bar
Abstract: Novel pyrido[3?,4?:4?,5?]pyrrolo[2?:4,5]imidazo[1,2-c]pyrimidine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrido[3?,4?:4?,5?]pyrrolo[3?,2?:4,5]imidazo[1,2-c]pyrimidine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
Abstract: The present invention provides mito-honokiol or mito-magnolol compounds, pharmaceutical compositions thereof, and methods of using the mito-honokiol or mito-magnolol compounds in the treatment of cancer.
Type:
Grant
Filed:
November 16, 2020
Date of Patent:
February 13, 2024
Assignees:
The Medical College of Wisconsin, Inc., Aix-Marseille Universite
Inventors:
Balaraman Kalyanaraman, Jacek Michal Zielonka, Gang Cheng, Micael J. Hardy, Olivier Ouari, Ming You
Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using imidazole-fused heterocycle amines. Some of the disclosed embodiments include imidazo-fused heterocycle compounds useful to treat leukemia and other hematopoietic disorders.
Abstract: Antiviral therapeutic compounds and compositions that may be used in methods of preventing and/or treating infection(s) caused by coronaviruses or influenza viruses.
Abstract: The present invention belongs to the field of pharmaceutical formulation, and particularly relates to an aripiprazole injectable suspension formulation having prolonged shelf life, and methods of using the formulation in treating schizophrenia and related diseases. In another aspect, the present invention also relates to a method of prolonging shelf life of an aripiprazole injectable suspension formulation.
Abstract: Disclosed herein are compositions comprising fixed doses of ETC-1002 and Ezetimibe. Also disclosed herein are methods for using fixed doses of ETC-1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.
Type:
Grant
Filed:
December 29, 2020
Date of Patent:
September 5, 2023
Assignee:
Esperion Therapeutics, Inc.
Inventors:
Roger Schofield Newton, Noah Laban Rosenberg, Diane Elaine MacDougall
Abstract: The present invention relates to methods of treating hypogonadism in a male subject through administering intranasally to the male subject an intranasal testosterone bio-adhesive gel formulation to deliver a therapeutically effective amount of testosterone. In particular, the testosterone therapy of the invention remains effective if an allergic rhinitis event occurs in the male during the treatment or when the male subject uses a topical nasal vasoconstrictor or a topical intranasal decongestant during the hypogonadism treatment. Further, the present invention relates to a method of preventing the occurrence of an allergic rhinitis event in a male, who is undergoing a hypogonadism treatment with an intranasal testosterone bio-adhesive gel. In certain embodiments, the intranasal testosterone bio-adhesive gel formulation according to the invention comprises 4.0% and 4.5% testosterone.
Abstract: The invention relates to the use of a selective ?2 adrenergic receptor antagonist for treating and preventing a tumor in a patient with von Hippel-Lindau syndrome. In particular, the invention relates to the use of an alkanolamine derivative or a pharmaceutically acceptable acid-addition salt thereof for treating and preventing a hemangioblastoma in VHL syndrome patients.
Type:
Grant
Filed:
August 6, 2018
Date of Patent:
August 22, 2023
Assignees:
ALIANZA ESPAÑOLA DE FAMILIAS DE VON HIPPEL-LINDAU-VHL, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS
Inventors:
Luisa María Botella Cubells, Virginia Albiñana Díaz, Karina Villar Gomez-De Las Heras
Abstract: A method of inducing anesthesia in a subject is provided. In some embodiments, the method provides administering to the subject via the respiratory system or via injection, an effective amount of a compound or a mixture of compounds selected from the group consisting of methyl-ethyl ethers, methyl-isopropyl ethers, and methyl-propyl ethers.
Type:
Grant
Filed:
September 25, 2020
Date of Patent:
July 11, 2023
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abstract: The present invention provides a pharmaceutical composition comprising 1-perfluorohexyl-octane (F6H8) for use in the therapy, treatment, prevention or amelioration of anterior or posterior blepharitis, preferably posterior blepharitis or symptoms associated therewith. Furthermore, the present invention provides a pharmaceutical kit for the therapy of anterior or posterior blepharitis or symptoms associated therewith.
Type:
Grant
Filed:
September 20, 2017
Date of Patent:
June 27, 2023
Assignee:
NOVALIQ GMBH
Inventors:
Bernhard Günther, Frank Löscher, Sonja Krösser
Abstract: A phenyl-containing compound, an intermediate thereof, a preparation method therefor and an application thereof. Provided is a compound represented by formula I or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4 and R5 are independently hydrogen, C1-C6 alkyl, C1-C6 alkoxy or C(?O)OR8; where R8 is C1-C4 alkyl; R6 is (II), (III) or (IV); and R7 is —OH, —NH2, —NHCH3, —N(CH3)2 or C1-4 alkoxy. The compound has a low critical micelle concentration (CMC) and good dilution resistance and is capable of enclosing an insoluble drug to form a small-molecule micelle having a high drug loading capacity and good stability.
Type:
Grant
Filed:
July 14, 2020
Date of Patent:
June 6, 2023
Assignees:
SHANGHAI MODERN PHARMACEUTICAL ENGINEERING RESEARCH CENTER CO., LTD., SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY